Vaxart (VXRT) Tops Q2 EPS by 2c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to Vaxart (VXRT) Tops Q2 EPS by 2c

Vaxart Provides Business Update and Reports Second Quarter 2025 Financial Results

August 13, 2025 4:05 PM EDT

Reported positive topline data from Phase 1 clinical trial evaluating Companys second-generation oral norovirus vaccine constructs, supporting potential for improved protection against infection   

Enrolled approximately 5,000 participants in COVID-19 Phase 2b trial prior to stop work order; Follow-up for all participants dosed, including 400-person sentinel cohort continues

Cash, cash equivalents and investments of $26.3 million as of June 30, 2025; Current runway into 2026

Conference call today at 4:30 p.m. ET

Live stockholder fireside chat scheduled on August 20, 2025 at 4:30 p.m. ET to answer frequently... More